Could Mushrooms’ Secondary Metabolites Ameliorate Alzheimer Disease? A Computational Flexible Docking Investigation
Journal of Medicinal Food · 2024
DOI: 10.1089/jmf.2023.0098 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Food, 2024. Verfasst von Ashaimaa Y Moussa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Alzheimer Disease, Molecular Docking Simulation, Agaricales, Acetylcholinesterase. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Herein, we highlight the significance of molecular modeling approaches prior to in vitro and in vivo studies; particularly, in diseases with no recognized treatments such as neurological abnormalities. Alzheimer disease is a neurodegenerative disorder that causes irreversible cognitive decline. Toxicity and ADMET studies were conducted using the Qikprop platform in Maestro software and Discovery Studio 2.0, respectively, to select the promising skeletons from more than 45 reviewed compounds isolated from mushrooms in the last decade. Using rigid and flexible molecular docking approaches such as induced fit docking (IFD) in the binding sites of β-secretase (BACE1) and acetylcholine esterase (ACHE), promising structures were screened through high precision molecular docking compared with standard drugs donepezil and (2E)-2-imino-3-methyl-5,5-diphenylimidazolidin-4-one (OKK) using Maestro and Cresset Flare platforms. Molecular interactions, binding distances, and RMSD values were measured to reveal key interactions at the binding sites of the two neurodegenerative enzymes. Analysis of IFD results revealed consistent bindings of dictyoquinazol A and gensetin I in the pocket of 4ey7 while inonophenol A, ganomycin, and fornicin fit quite well in 4dju demonstrating binding poses very close to native ligands at ACHE and BACE1. Respective key amino acid contacts manifested the least steric problems according to their Gibbs free binding energies, Glide XP scores, RMSD values, and molecular orientation respect to the key amino acids. Molecular dynamics simulations further confirmed our findings and prospected these compounds to show significant in vitro results in their future pharmacological studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacognosy, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.
- Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- Single Cell Research Center, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Ashaimaa Y Moussa
Zitieren
APA
Moussa, A. Y., Alanzi, A. R., Riaz, M., & Fayez, S. (2024). Could Mushrooms’ Secondary Metabolites Ameliorate Alzheimer Disease? A Computational Flexible Docking Investigation. Journal of Medicinal Food. https://doi.org/10.1089/jmf.2023.0098
Vancouver
Moussa AY, Alanzi AR, Riaz M, Fayez S. Could Mushrooms’ Secondary Metabolites Ameliorate Alzheimer Disease? A Computational Flexible Docking Investigation. Journal of Medicinal Food. 2024. doi:10.1089/jmf.2023.0098
BibTeX
@article{Moussa2024,
author = {Moussa, Ashaimaa Y and Alanzi, Abdullah R and Riaz, Muhammad and Fayez, Shaimaa},
title = {Could Mushrooms’ Secondary Metabolites Ameliorate Alzheimer Disease? A Computational Flexible Docking Investigation},
journal = {Journal of Medicinal Food},
year = {2024},
doi = {10.1089/jmf.2023.0098}
}
EUVIMED